Literature DB >> 17119544

Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants.

Giuseppe Pignataro1, Francesca E Studer, Andrew Wilz, Roger P Simon, Detlev Boison.   

Abstract

Protective mechanisms of the brain may reduce the extent of injury after focal cerebral ischemia. Here, we explored in a mouse model of focal cerebral ischemia potential synergistic neuroprotective effects of two mediators of neuroprotection: (i) neuronal or glial precursor cells and (ii) the inhibitory neuromodulator adenosine. Embryonic stem (ES) cells, engineered to release adenosine by biallelic disruption of the adenosine kinase gene, and respective wild-type cells were induced to differentiate into either neural or glial precursor cells and were injected into the striatum of mice 1 week before middle cerebral artery occlusion. All stem cell-derived graft recipients were characterized by a significant reduction in infarct volume, an effect that was augmented by the release of adenosine. Neuroprotection was strongest in adenosine-releasing glial precursor cell recipients, which were characterized by an 85% reduction of the infarct area. Graft-mediated neuroprotection correlated with a significant improvement of general and focal neurologic scores. Histologic analysis before and after ischemia revealed clusters of implanted cells within the striatum of all treated mice. We conclude that ES cell derived adenosine-releasing brain implants provide neuroprotection by synergism of endogenous precursor cell-mediated effects and paracrine adenosine release.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119544     DOI: 10.1038/sj.jcbfm.9600422

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  23 in total

1.  Adenosine dysfunction and adenosine kinase in epileptogenesis.

Authors:  Detlev Boison
Journal:  Open Neurosci J       Date:  2010-01-01

2.  Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis.

Authors:  Tianfu Li; Gaoying Ren; David L Kaplan; Detlev Boison
Journal:  Epilepsy Res       Date:  2009-02-12       Impact factor: 3.045

3.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

4.  Mouse Microsurgery Infusion Technique for Targeted Substance Delivery into the CNS via the Internal Carotid Artery.

Authors:  Ana R Leda; Levy Dygert; Luc Bertrand; Michal Toborek
Journal:  J Vis Exp       Date:  2017-01-31       Impact factor: 1.355

Review 5.  Purinergic signaling in embryonic and stem cell development.

Authors:  Geoffrey Burnstock; Henning Ulrich
Journal:  Cell Mol Life Sci       Date:  2011-01-08       Impact factor: 9.261

6.  RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION).

Authors:  Shimin Liu; Gehua Zhen; Bruno P Meloni; Kym Campbell; H Richard Winn
Journal:  J Exp Stroke Transl Med       Date:  2009-01-01

7.  HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage.

Authors:  Luigi Formisano; Giusy Laudati; Natascia Guida; Luigi Mascolo; Angelo Serani; Ornella Cuomo; Maria Cantile; Francesca Boscia; Pasquale Molinaro; Serenella Anzilotti; Vincenzo Pizzorusso; Gianfranco Di Renzo; Giuseppe Pignataro; Lucio Annunziato
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-07       Impact factor: 6.200

8.  Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.

Authors:  Gaoying Ren; Tianfu Li; Jiang Quan Lan; Andrew Wilz; Roger P Simon; Detlev Boison
Journal:  Exp Neurol       Date:  2007-08-02       Impact factor: 5.330

9.  Synchronous GABA-receptor-dependent potentials in limbic areas of the in-vitro isolated adult guinea pig brain.

Authors:  Laura Uva; Massimo Avoli; Marco de Curtis
Journal:  Eur J Neurosci       Date:  2009-03       Impact factor: 3.386

Review 10.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.